Last reviewed · How we verify
dose-escalated selinexor treatment
dose-escalated selinexor treatment is a Small molecule drug developed by Sheba Medical Center. It is currently in Phase 1 development. Also known as: KPT-330.
At a glance
| Generic name | dose-escalated selinexor treatment |
|---|---|
| Also known as | KPT-330 |
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dose-escalated selinexor treatment CI brief — competitive landscape report
- dose-escalated selinexor treatment updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI
Frequently asked questions about dose-escalated selinexor treatment
What is dose-escalated selinexor treatment?
dose-escalated selinexor treatment is a Small molecule drug developed by Sheba Medical Center.
Who makes dose-escalated selinexor treatment?
dose-escalated selinexor treatment is developed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).
Is dose-escalated selinexor treatment also known as anything else?
dose-escalated selinexor treatment is also known as KPT-330.
What development phase is dose-escalated selinexor treatment in?
dose-escalated selinexor treatment is in Phase 1.
Related
- Manufacturer: Sheba Medical Center — full pipeline
- Also known as: KPT-330
- Compare: dose-escalated selinexor treatment vs similar drugs
- Pricing: dose-escalated selinexor treatment cost, discount & access